News Home > News

July 19, 2012
Caspase Inhibitor Enters Clinical Trial in Islet Transplantation as Treatment for Diabetes

July 17, 2012
Conatus Pharmaceuticals Appoints Daniel Ripley as Head of Corporate Development

July 12, 2012
Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics

November 1, 2011
Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer

October 25, 2011
Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027

April 12, 2011
Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing

March 31, 2011
Conatus Pharmaceuticals Presents Results From A Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders

March 11, 2011
Conatus Pharmaceuticals will display HCV clinical trial data at the International Liver Congress™ (EASL) in March

February 17, 2011
Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)

February 11, 2011
Conatus pharmaceuticals completes $20 million Series B private placement financing

July 30, 2010
Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary